Long COVID Clinical Trial
— PrENTOfficial title:
Prevalence Study of ENT-related Diseases in Conscripts at the Military Induction Board
The aim of the present study will be to evaluate in conscripts at the military induction board the prevalence of rhinosinusitis, the prevalence of HPV vaccinations, the prevalence of hearing impairments and the prevalence of long-COVID symptoms and further, to evaluate different factors that influence on the one hand the prevalence (urban-bred, non-urban-bred) and on the other hand symptoms (ENT-surgeries in medical history). Further, we want to evaluate if there is a correlation between subjective symptoms and apparated-based diagnostic investigations. Therefore, questionnaires and data of medical examinations, aquired routinely at the military induction board, will be analysed.
Status | Not yet recruiting |
Enrollment | 10000 |
Est. completion date | March 31, 2026 |
Est. primary completion date | December 1, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 17 Years to 19 Years |
Eligibility | Inclusion Criteria: - participation of the military induction board of conscripts - consent for participation obtained by the conscripts - completed questionnaire (with at least 50% completeness of each subcategory) - participation of medical examination Exclusion Criteria: - no consent for participation in the study by the conscripts - incomplete questionnaire (with less than 50% completeness of each subcategory) - no participation of medical examination. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Medical University of Graz |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of rhinosinusitis | To assess whether there is a difference in prevalence of rhinosinusitis in urban-bred conscripts compared to non-urban-bred conscripts. | Through data collection, an average of 1 week | |
Primary | Prevalence of human papilloma virus vaccination | To assess whether there is a difference in prevalence of human papilloma virus vaccinations in urban-bred conscripts compared to non-urban-bred conscripts. | Through data collection, an average of 1 week | |
Primary | Prevalence of hearing impairment | To assess whether there is a difference in prevalence of hearing impairment in urban-bred conscripts compared to non-urban-bred conscripts. | Through data collection, an average of 1 week | |
Primary | Prevalence of long-COVID disease | To assess whether there is a difference in prevalence of long-COVID disease in vaccinated conscripts compared to no-vaccinated conscripts. | Through data collection, an average of 1 week | |
Secondary | Prevalence of rhinosinusitis | To assess prevalence of rhinosinusitis in conscripts at the military induction board | Through data collection, an average of 1 week | |
Secondary | Prevalence of rhinosinusitis | To assess the different symptoms of rhinosinusitis in conscripts at the military induction board | Through data collection, an average of 1 week | |
Secondary | Prevalence of rhinosinusitis | To assess the prevalence of rhinosinusitis in conscripts with previous ENT-surgeries | Through data collection, an average of 1 week | |
Secondary | Prevalence of rhinosinusitis | To assess differences in symptoms in rhinosinusitis in conscripts with previous ENT-surgeries | Through data collection, an average of 1 week | |
Secondary | Prevalence of rhinosinusitis | To assess the combined prevalence of rhinosinusitis and chronic pulmonary diseases in conscripts | Through data collection, an average of 1 week | |
Secondary | Prevalence of rhinosinusitis | To assess the difference in prevalence of subjective symptoms of rhinosinusitis compared to objective (apparatus based and laboratory based) symptoms of rhinosinusitis | Through data collection, an average of 1 week | |
Secondary | Prevalence of rhinosinusitis | To analyse demographic data in conscripts with rhinosinusitis | Through data collection, an average of 1 week | |
Secondary | Prevalence of human papilloma virus vaccines | To assess the prevalence of HPV vaccines among conscripts at the military induction board | Through data collection, an average of 1 week | |
Secondary | Prevalence of human papilloma virus vaccines | To assess knowledge about HPV and HPV vaccinations and in dependent of that prevalence of HPV vaccines among conscripts at the military induction board | Through data collection, an average of 1 week | |
Secondary | Prevalence of hearing impairment | To assess the prevalence of hearing impairment in conscripts at the military induction board | Through data collection, an average of 1 week | |
Secondary | Prevalence of hearing impairment | To assess the difference in prevalence of subjective symptoms of hearing impairment compared to objective (apparatus based and laboratory based) signs of hearing impairment | Through data collection, an average of 1 week | |
Secondary | Prevalence of hearing impairment | To analyse demographic data in conscripts with hearing impairment | Through data collection, an average of 1 week | |
Secondary | Prevalence of long-COVID | To assess the prevalence of long-COVID in conscripts at the military induction board | Through data collection, an average of 1 week | |
Secondary | Prevalence of long-COVID | To assess different symptoms of long-COVID in conscripts at the military induction board | Through data collection, an average of 1 week | |
Secondary | Prevalence of COVID-19 infection | To assess the prevalence of previous COVID 19 infections in conscripts at the military induction board | Through data collection, an average of 1 week | |
Secondary | Prevalence of long-COVID | To analyse demographic data in conscripts with long-COVID | Through data collection, an average of 1 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05926505 -
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Completed |
NCT05552612 -
Health-related Quality of Life and Long COVID
|
||
Completed |
NCT05531019 -
COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A
|
N/A | |
Not yet recruiting |
NCT04949386 -
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
|
Phase 2 | |
Recruiting |
NCT06118112 -
Living With Long COVID: LONGCOVID-EXPERIENCE
|
||
Completed |
NCT05185674 -
Sociodemographic, Clinical, Quality of Life and Health Care Conditions in COVID-19 Survivors.
|
||
Active, not recruiting |
NCT05965739 -
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
|
N/A | |
Active, not recruiting |
NCT05965752 -
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
|
N/A | |
Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
Recruiting |
NCT05606211 -
Pain in Long COVID-19: The Role of Sleep
|
||
Active, not recruiting |
NCT05713266 -
Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
|
||
Completed |
NCT05601180 -
Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.
|
N/A | |
Completed |
NCT05679505 -
Vagus Nerve Stimulation for Post-COVID Syndrome
|
N/A | |
Not yet recruiting |
NCT06045338 -
Mind Body Intervention for Long COVID
|
N/A | |
Recruiting |
NCT06091358 -
Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation.
|
N/A | |
Recruiting |
NCT05566392 -
Longterm Influence of Pediatric Long COVID Syndrome
|
||
Recruiting |
NCT05855369 -
Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss
|
Phase 2/Phase 3 | |
Recruiting |
NCT05572346 -
Digital App for Telerehabilitation in Respiratory Diseases
|
||
Recruiting |
NCT06316843 -
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
|
Phase 2 |